Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
cancer
3
×
detroit blog main
detroit top stories
diagnostics
3
×
indiana blog main
indiana top stories
life sciences
merck
national
national blog main
national top stories
new york blog main
new york top stories
novartis
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
3
×
texas top stories
wisconsin blog main
wisconsin top stories
abbvie
alzheimer's disease
amgen
bristol-myers squibb
cell therapy
clinical trials
deals
eli lilly
gilead sciences
What
bio
drug
roundup
new
acquisitions
advantages
approval
bar
biggest
biogen’s
biopharmaceutical
brings
build
buy
ceo
companies
company’s
convo
daniel
debut
dyne’s
earlier
expect
failures
gamble
gilead
littered
market
medco’s
microbiome
mover
moves
nash
news
openly
o’day
patients
payers
physicians
pipeline
Language
unset
Current search:
diagnostics
×
cancer
×
" texas blog main "
×
@xconomy.com
3 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More